State-of-the-Art and Problems in Development of Automated Screening Systems in Personalized Medicine and Oncology
- 1 November 2018
- conference paper
- Published by Institute of Electrical and Electronics Engineers (IEEE)
- p. 140-142
Abstract
Despite the fact that oncology issues are among the most actively studied, the problem of tumor resistance to the therapy remains very relevant at the moment. Currently, there are no validated models while known systems are generally focused on detecting few particular conditions - either to assess the composition of the gaseous medium, humidity and temperature, or to assess the dissolved gases and pH in the flowing nutrient medium of bioreactors, or to assess the content of intracellular oxygen. These systems lack tracking of the dynamic parameters of 3D systems and the ability to operate such systems, including decision-making modules. To validate advanced cellular tumor models, one needs a device that should have advantages over modern commercially available models, this system has to be better in terms of sterile work, autonomy, cost-effectiveness, applicability for experiments and microscopy. Based on several types of physical, chemical and biological sensors, the new generation screening system will allow one to reveal in the foreseeable future additional indicators of the functional activity of tumor cells and dependence on changes in the extracellular matrix, metabolic activity of cells during their growth, migration, transformation and response to therapy on the basis of personalized 3D cellular tumor model.Keywords
This publication has 4 references indexed in Scilit:
- Breakthroughs in modern cancer therapy and elusive cardiotoxicity: Critical research‐practice gaps, challenges, and insightsMedicinal Research Reviews, 2017
- Tumour-on-a-chip: microfluidic models of tumour morphology, growth and microenvironmentJournal of The Royal Society Interface, 2017
- Non-invasive imaging and monitoring cardiotoxicity of cancer therapeutic drugsJournal of Nuclear Cardiology, 2012
- Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancerJournal of Clinical Investigation, 2009